OFER LEVY, ARİE APEL, HOSSAM ALHDOR, AVRAHAM MİZRACHİ, NANCY AGMON LEVİN, MAYA KOREN MİCHOWİTZ, MİRİT AMİT VAZİNA
European Journal of Rheumatology - 2022;9(4):217-220
Macrophage activation syndrome is the most frequent life-threatening complication of adult-onset Still’s disease. This is a nearly fatal case of a young patient, which has been refractory to corticosteroids, anakinra, tocilizumab, cyclosporine A, and etoposide, but eventually responded miraculously to salvage therapy with ruxolitinib. We review recent pertinent data related to the therapeutic value of ruxolitinib for macrophage activation syndrome triggered by adult-onset Still’s disease.
